tiprankstipranks
Trending News
More News >

Aquestive Therapeutics price target lowered to $8 from $10 at Lake Street

Lake Street analyst Thomas Flaten lowered the firm’s price target on Aquestive Therapeutics (AQST) to $8 from $10 and keeps a Buy rating on the shares after the company reported Q4 revenues below the firm’s estimate and consensus. However, the focus on Aquestive “is (and, if not, should be)” Anaphylm and the NDA submission process is underway and will be completed this quarter, the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue